Login to Your Account

One of These Drugs Is Not Like the Others

Market Potential Sets Home for Abuse-Resistant Pain Drugs

By Brian Orelli
Contributing Writer

Monday, October 28, 2013

Last week Pfizer Inc. told Pain Therapeutics Inc. that it plans to continue development of the abuse-resistant pain medication Remoxy (oxycodone) extended-release capsules CII.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription